Share This Article:

Imaging of Insulitis in NOD Mice with IL-2-Gd-DTPA and 1.5 T MRI

Abstract Full-Text HTML Download Download as PDF (Size:206KB) PP. 43-49
DOI: 10.4236/ami.2011.13006    4,053 Downloads   10,753 Views   Citations

ABSTRACT

To explore the possibility to use 1.5 T MRI in imaging of accumulating gadolinium (Gd) into inflamed en- docrine pancreas (insulitis), we compared intravenously delivered IL-2-Gd-DTPA and Gd-DTPA (Magne- vist®) in phenotypically healthy 12 weeks old female non-obese diabetic (NOD) mice. At 1 to 48 h after the injection mice were sacrificed and the pancreas-to-background ratio was determined using MRI. In addition Gd concentration of the pancreas and plasma were measured. The pancreas-to-plasma ratio of Gd was 25-fold 24 h after the i.v. injection of IL-2-Gd-DTPA. At the same time the pancreas-to-background ratio measured with 1.5T MRI was 1.5-times higher in the NOD mice receiving IL-2-Gd-DTPA than Magnevist® (271 ± 37 vs. 183 ± 0,1, P = 0.04) indicating that sufficient differences may exist between IL-2-Gd-DTPA accumulating in the pancreas and in the surrounding tissues to support the use of MRI for imaging of pan- creatic insulitis.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

T. Kalliokoski, E. Svedström, J. Saunavaara, A. Roivainen, M. Kankaanpää, H. Oivanen, P. Nuutila and O. Simell, "Imaging of Insulitis in NOD Mice with IL-2-Gd-DTPA and 1.5 T MRI," Advances in Molecular Imaging, Vol. 1 No. 3, 2011, pp. 43-49. doi: 10.4236/ami.2011.13006.

References

[1] P. Pozzilli, A. Signore, A. J. Williams and P. E. Beales, “NOD Mouse Colonies around the World—Recent Facts and Figures,” Immunology Today, Vol. 14, No. 5, 1993, pp. 193-196. doi:10.1016/0167-5699(93)90160-M
[2] E. F. Lampeter, A. Signore, E. A. Gale and P. Pozzilli, “Lessons from the NOD Mouse for the Pathogenesis and Immunotherapy of Human Type 1 (Insulin-Dependent) Diabetes Mellitus,” Diabetologia, Vol. 32, No. 10, 1989, pp. 703-708. doi:10.1007/BF00274528
[3] Y. Koide, T. Kaidoh, M. Nakamura and T. O. Yoshida, “Molecular Analysis of the Pathogenesis of Autoimmune Insulitis in NOD Mice,” The Tohoku Journal of Experi-mental Medicine, Vol. 173, No. 1, 1994, pp. 157-170. doi:10.1620/tjem.173.157
[4] G. S. Eisenbarth, “Type I Diabetes Mellitus. A Chronic Autoimmune Disease,” The New England Journal Medi-cine, Vol. 314, No. 21, 1986, pp. 1360-1368.
[5] A. Signore, E. Procaccini, A. M. Toscano, E. Ferretti, A. J. Williams, P. E. Beales, P. Cugini and P. Pozzilli, “His-tological Study of Pancreatic Beta-Cell Loss in Relation to the Insulitis Process in the Non-Obese Diabetic Mouse,” Histochemistry, Vol. 101, No. 4, 1994, pp. 263- 269. doi:10.1007/BF00315913
[6] S. Makino, K. Kunimoto, Y. Muraoka, Y. Mizushima, K. Katagiri and Y. Tochino, “Breeding of a Non-Obese, Di-abetic Strain of Mice,” Experimental Animals, Vol. 29, No. 1, 1980, pp. 1-13.
[7] N. Hatamori, K. Yokono, M. Nagata, K. Doi and S. Baba, “Interleukin 2/Interleukin 2 Receptor System in Type 1 Diabetes,” Diabetes Research and Clinical Practice, Vol. 7, Supplement 1, 1989, pp. S67-S72. doi:10.1016/0168-8227(89)90090-9
[8] P. Bedossa, A. Bendelac, J. F. Bach and C. Carnaud, “Syngeneic T Cell Transfer of Diabetes into NOD New-born Mice: In Situ Studies of the Autoimmune Steps Leading to Insulin-Producing Cell Destruction,” European Journal of Immunology, Vol. 19, No. 10, 1989, pp. 1947-1951. doi:10.1002/eji.1830191028
[9] A. Signore, M. Chianelli, A. Toscano, L. Monetini, G. Ronga, C. C. Nimmon, K. E. Britton, P. Pozzilli and M. Negri, “A Radiopharmaceutical for Imaging Areas of Lymphocytic Infiltration: 123I-Interleukin-2. Labelling Procedure and Animal Studies,” Nuclear Medicine Communications, Vol. 13, No. 10, 1992, pp. 713-722.
[10] O. Rolandsson, T. Stigbrand, K. Riklundahlstrom, J. Eary and C. Greenbaum, “Accumulation of(125)Iodine Labeled Interleukin-2 in the Pancreas of NOD Mice,” Journal of Autoimmunity, Vol. 17, No. 4, 2001, pp. 281- 287. doi:10.1006/jaut.2001.0555
[11] J. Virostko, E. D. Jansen and A. C. Powers, “Current Status of Imaging Pancreatic Islets,” Current Diabetes Reports, Vol. 6, No. 4, 2006, pp. 328-332. doi:10.1007/s11892-006-0069-9
[12] A. Moore, J. Grimm, B. Han and P. Santamaria, “Tracking the Recruitment of Diabetogenic CD8+ T-cells to the Pancreas in Real Time,” Diabetes, Vol. 53, No. 6, 2004, pp. 1459-1466. doi:10.2337/diabetes.53.6.1459
[13] M. Srinivas, P. A. Morel, L. A. Ernst, D. H. Laidlaw and E. T. Ahrens, “Fluorine-19 MRI for Visualization and Quantification of Cell Migration in a Diabetes Model,” Magnetic Resonance Medicine, Vol. 58, No. 4, 2007, pp. 725-734. doi:10.1002/mrm.21352
[14] M. C. Denis, U. Mahmood, C. Benoist, D. Mathis and R. Weissleder, “Imaging Inflammation of the Pancreatic Islets in Type 1 Diabetes,” Proceeding of the National Academy Sciences of the United States of American, Vol. 101, No. 34, 2004, pp. 12634-12639.
[15] A. Khurana, J. F. Greene, Jr. and W. A. High, “Quantifi-cation of Gadolinium in Nephrogenic Systemic Fibrosis: Re-examination of a Reported Cohort with Analysis of Clinical Factors,” Journal of the American Academy of Dermatology, Vol. 59, No. 2, 2008, pp. 218-224. doi:10.1016/j.jaad.2008.04.010
[16] H. J. Weinmann, R. C. Brasch, W. R. Press and G. E. Wesbey, “Characteristics of Gadolinium-DTPA Complex: A Potential NMR Contrast Agent,” American Journal of Roentgenology, Vol. 142, No. 3, 1984, pp. 619-624.
[17] J. Brailsford, J. Ward, A. G. Chalmers, J. Ridgway and P. J. Robinson, “Dynamic MRI of the Pancreas—Ga- doli-nium Enhancement in Normal Tissue,” Clinical radiology, Vol. 49, No. 2, 1994, pp. 104-108. doi:10.1016/S0009-9260(05)83450-6
[18] R. Weissleder, A. Moore, U. Mahmood, R. Bhorade, H. Benveniste, E. A. Chiocca and J. P. Basilion, “In Vivo Magnetic Resonance Imaging of Transgene Expression,” Nature Medicine, Vol. 6, No. 3, 2000, pp. 351-355. doi:10.1038/73219
[19] J. L. Gaglia, A. R. Guimaraes, M. Harisinghani, S. E. Turvey, R. Jackson, C. Benoist, D. Mathis and R. Weis-sleder, “Noninvasive Imaging of Pancreatic Islet Inflam-mation in Type 1A Diabetes Patients,” The Journal of Clinical Investigation, Vol. 121, No. 1, 2011, pp. 442- 445. doi:10.1172/JCI44339
[20] T. Vial and J. Descotes, “Clinical Toxicity of Interleu-kin-2,” Drug Safety, Vol. 7, No. 6, 1992, pp. 417-433. doi:10.2165/00002018-199207060-00004
[21] P. Marckmann, L. Skov, K. Rossen, J. G. Heaf and H. S. Thomsen, “Case-Control Study of Gadodiamide-Related Nephrogenic Systemic Fibrosis,” Nephrology Dialysis Transplantation, Vol. 22, No. 11, 2007, pp. 3174-3178. doi:10.1093/ndt/gfm261
[22] H. S. Thomsen and P. Marckmann, “Extracellular Gd-CA: Differences in Prevalence of NSF,” European Journal of Radiology, Vol. 66, No. 2, 2008, pp. 180-183. doi:10.1016/j.ejrad.2008.01.024
[23] M. W. Konrad, G. Hemstreet, E. M. Hersh, P. W. Mansell, R. Mertelsmann, J. E. Kolitz and E. C. Bradley, “Pharmacokinetics of Recombinant Interleukin 2 in Hu-mans,” Cancer Research, Vol. 50, No. 7, 1990, pp. 2009- 2017.
[24] J. H. Donohue and S. A. Rosenberg, “The Fate of Inter-Leukin-2 after in Vivo Administration,” The Journal of Immunology, Vol. 130, No. 5, 1983, pp. 2203-2208.
[25] A. Signore, A. Picarelli, A. Annovazzi, K. E. Britton, A. B. Grossman, E. Bonanno, B. Maras, D. Barra and P. Pozzilli, “123I-Interleukin-2: Biochemical Characterization and in Vivo Use for Imaging Autoimmune Diseases,” Nuclear Medicine Communications, Vol. 24, No. 3, 2003, pp. 305-316. doi:10.1097/00006231-200303000-00011
[26] A. Signore, A. Cooke, P. Pozilli, G. Butcher, E. Simpson and P. C. L. Beverley, “Class-II and IL-2 Receptor Posi-tive Cells in the Pancreas of NOD Mice,” Diabetologia, Vol. 30, No. 11, 1987, pp. 902-905.
[27] T. Kalliokoski, O. Simell, M. Haaparanta, T. Viljanen, O. Solin, J. Knuuti and P. Nuutila, “An Autoradiographic Study of [(18)F]FDG Uptake to Islets of Langerhans in NOD Mouse,” Diabetes Research and Clinical Practice, Vol. 70, No. 3, 2005, pp. 217-24. doi:10.1016/j.diabres.2005.04.008

  
comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.